CER Daily Newsfeed

Podcast: Head of the Leerink Center for Pharmacoeconomics Melanie Whittington, PhD

(11/21, Leerink Partners) comments “...[Melanie Whittington, PhD, Head of the Leerink Center of Pharmacoeconomics:] So, when I started my PhD, I had never heard of pharmacoeconomics, but one of my early classes was an introduction to health economics. At the course there was, in the course there was a guest lecturer who came in to talk about pharmacoeconomics. And in a lecture, he pulled up a cost effectiveness analysis model in Microsoft Excel, and I was absolutely fascinated with it...And so if there are any other pharmacoeconomists listening, that guest lecturer was Dr. John Campbell, who’s now the chief scientific officer of the National Pharmaceutical Council. And I’m fortunate to still collaborate with him to this day.” Full

HTA Bodies In England, US and Canada Collaborate On Developing Health Economic Methods

(11/21, Leela Barham, Pink Sheet) reports “...Nick Crabb, chief scientific officer at England’s NICE, explained that there is increased interest in the methods and value frameworks used in HTA because of the current ‘era of unprecedented innovation in medicines and health technologies.’ In response, ‘HEMA will provide an authoritative, international voice in key methodological areas where there are high levels of potential, controversy and challenge,’ he told the Pink Sheet.” Subscription Required